KindredBio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health

/in , , /by

SAN FRANCISCO, CA and WALTHAM, MA, USA. (March 31, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and KindredBio will develop and commercialize these antibodies. KindredBio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to KindredBio.

Read more

Kindred Bio Announces Initiation of Pivotal Clinical Study for SentiKin™ in Dogs

/in , , /by

SentiKin™, KindredBio’s third lead product candidate, is being developed for the treatment of post-operative pain in dogs.

SAN FRANCISCO, California. (March 28, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs.

Read more

KindredBio Appoints Dr. Blake Hawley as Chief Commercial Officer, Announces Upcoming Inclusion in Russell 2000

/in , , /by

Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill’s Pet Nutrition, to Join KindredBio

SAN FRANCISCO, California. (March 24, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014.

Read more

KindredBio Announces Proposed Public Offering

/in , , /by

SAN FRANCISCO, California. (March 18, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Read more

Kindred Biosciences Announces Fourth Quarter and Year End 2013 Financial Results

/in , , /by

San Francisco, CA. (March 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. KindredBio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results.

Read more

KindredBio to Present at Roth Capital Partners 26th Annual Growth Stock Conference

/in , , /by

SAN FRANCISCO, California. (March 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26th Annual Growth Stock Conference in Dana Point, CA:

Read more